Biogen Idec Finalizes Phase III Plans For Aducanumab In Alzheimer’s
Though performance of a middle 6 mg/kg dose cohort just disappointed investors in the Phase Ib PRIME trial, company is confident with using this regimen in two large Phase III studies.
You may also be interested in...
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.